Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever.

Abstract

Herein, we reported our experience in colchicine-resistant familial Mediterranean fever (FMF) patients who are treated with anti-interleukin-1 (IL-1) drugs. A retrospective review of medical records of anti-IL-1 recipients was performed. The main clinical characteristics of these patients and the evolution after anti-IL-1 were recorded. There were 20 patients (11 male [M] and 9 female [F]). Despite regular colchicine treatment, median number of attacks per month and per year was 1 (1-4) and 12 (4-50), respectively. Twelve patients were receiving anakinra, and eight patients were treated with canakinumab. The number of monthly and yearly attacks after IL-1 treatment was significantly decreased after the biologic agent (p < 0.05). One patient did not respond to the treatment, and one patient developed serious infection during anti-IL-1. We also observed a significant decrease in proteinuria in the amyloidosis complicated FMF patients. Anti-IL-1 targeting drugs seem safe and effective therapies in colchicine-resistant FMF.

• Authors: Pinar Cetin, Ismail Sari, Betul Sozeri, Ozlem Cam, Merih Birlik, Nurullah Akkoc, Fatos Onen, Servet Akar
• Journal: Inflammation (Inflammation) Vol. 38 Issue 1 Pg. 27-31 (Feb 2015) ISSN: 1573-2576 [Electronic] United States
• PMID: 25139580 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Interleukin 1 Receptor Antagonist Protein
• Interleukin-1
• canakinumab

Topics

• Adolescent
• Adult
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Drug Delivery Systems (methods)
• Familial Mediterranean Fever (diagnosis, drug therapy, metabolism)
• Female
• Humans
• Interleukin 1 Receptor Antagonist Protein (administration & dosage)
• Interleukin-1 (antagonists & inhibitors, metabolism)
• Male
• Middle Aged
• Retrospective Studies
• Treatment Outcome
• Young Adult